Poseida Therapeutics, Inc. (PSTX)

Poseida Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	49.34	44.47	81.38	206.33	83.97	87.78
Short-Term Investments	181.51	167.73	201.12	-	225.19	37.53
Cash & Short-Term Investments	230.85	212.2	282.49	206.33	309.15	125.32
Cash Growth	-3.34%	-24.88%	36.92%	-33.26%	146.69%	312.30%
Receivables	14.75	9.01	9.09	-	-	-
Prepaid Expenses	5.1	1.5	2	2.71	2.58	0.88
Other Current Assets	-	3.76	4.98	4.84	2.26	0.98
Total Current Assets	250.7	226.48	298.56	213.87	314	127.18
Property, Plant & Equipment	36.42	40.78	46.67	48.23	48.32	10.86
Goodwill	4.23	4.23	4.23	4.23	4.23	4.23
Other Intangible Assets	1.32	1.32	1.32	1.32	1.32	1.32
Other Long-Term Assets	0.91	1.08	1.06	1.66	3.62	3.41
Total Assets	293.58	273.89	351.84	269.31	371.48	147

Liabilities

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Accounts Payable	5.2	3.27	2.23	8.96	0.76	4.93
Accrued Expenses	25.37	27.7	22.18	21.05	22.62	12.26
Current Portion of Long-Term Debt	-	-	-	-	-	3
Current Portion of Leases	6.09	5.95	5.87	6.34	4.81	-
Current Unearned Revenue	37.27	31.01	19.72	4.5	-	-
Other Current Liabilities	4.34	3.4	3.89	2.49	1.84	1.67
Total Current Liabilities	78.27	71.32	53.89	43.34	30.03	21.86
Long-Term Debt	58.91	58.59	58.25	29.36	31.63	28.64
Long-Term Leases	17.73	20.88	24.64	25.5	25.37	-
Long-Term Unearned Revenue	48.4	16.78	25.33	13.26	23.76	19.59
Long-Term Deferred Tax Liabilities	-	-	-	0.06	0.06	0.06
Other Long-Term Liabilities	3.05	2.61	2.15	1.59	-1.33	2.92
Total Liabilities	206.37	170.18	164.24	113.1	109.52	73.06

Shareholders' Equity

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Common Stock	0.01	0.01	0.01	0.01	0.01	0
Additional Paid-In Capital	716.53	697.86	658.6	563.06	543.84	2.69
Retained Earnings	-629.7	-594.29	-470.86	-406.86	-281.89	-152.22
Comprehensive Income & Other	0.38	0.13	-0.15	-	0.01	0.02
Total Common Equity	87.21	103.7	187.6	156.21	261.97	-149.51
Shareholders' Equity	87.21	103.7	187.6	156.21	261.97	73.93
Total Liabilities & Equity	293.58	273.89	351.84	269.31	371.48	147

Additional Metrics

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Total Debt	82.73	85.42	88.75	61.2	61.82	31.64
Net Cash (Debt)	148.13	126.78	193.74	145.13	247.34	93.68
Net Cash Growth	-2.92%	-34.56%	33.50%	-41.32%	164.03%	728.35%
Net Cash Per Share	1.54	1.41	2.69	2.33	6.87	7.42
Filing Date Shares Outstanding	97.47	96.49	86.53	62.55	62.11	13.2
Total Common Shares Outstanding	97.41	95.64	85.96	62.52	61.86	13.2
Working Capital	172.44	155.16	244.68	170.54	283.97	105.32
Book Value Per Share	0.90	1.08	2.18	2.50	4.23	-11.33
Tangible Book Value	81.66	98.15	182.05	150.66	256.42	-155.06
Tangible Book Value Per Share	0.84	1.03	2.12	2.41	4.15	-11.75
Machinery	26.05	23.75	21.06	17.28	13.73	7.97
Construction In Progress	-	-	-	-	0.38	4.73
Leasehold Improvements	14.17	14.11	14.01	13.91	13.83	0.17

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Sep 30, 2024

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jan 1, 2000

Data Sources Report a data error